Post-earnings recap
Reported
Mon, Mar 29, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
13%
This earnings report shows that Vaxcyte Inc is still in the development phase, with losses continuing as expected. The stock reacted negatively, dropping 4.34%, likely due to the lack of revenue information and no updated guidance. Investors will be looking for more clarity in future reports regarding product development and potential revenue streams.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.41 | N/A | +14.58% |
| Revenue | N/A | N/A | N/A |
Management remains focused on advancing their pipeline despite the current losses. They emphasized the importance of upcoming trials and research.
Management highlighted ongoing efforts in product development.
They acknowledged challenges but expressed confidence in future trials.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—